- BIOVECTRA and Revolution Biomanufacturing have entered a collaboration combining mRNA sequence design technologies with end-to-end GMP manufacturing capabilities.
- The partnership provides customers with a seamless pathway from mRNA sequence optimisation to sterile drug product manufacturing.
BIOVECTRA, a subsidiary of Agilent Technologies Inc., has announced a collaboration with Revolution Biomanufacturing Inc. to integrate mRNA optimisation technologies into its contract manufacturing capabilities. The agreement grants BIOVECTRA access to Revolution Biomanufacturing’s proprietary platforms for optimising untranslated regions (UTRs) and codon usage to improve mRNA stability and translational efficiency.
The partnership creates a unified workflow covering mRNA sequence design, process development, scale-up, and GMP manufacturing of plasmid DNA, mRNA, lipid nanoparticles, and sterile drug product. The collaboration aims to provide sponsors with a single-source solution from discovery through to clinical production.
Through a single agreement, customers will have access to Revolution Biomanufacturing’s AI-driven codon-optimised DNA sequence design and proprietary UTR technologies, which have demonstrated three- to fivefold increases in protein expression. BIOVECTRA will complement these technologies with its integrated GMP manufacturing capabilities, including analytical testing and sterile fill/finish.
“This collaboration strengthens our ability to support innovators developing the next generation of mRNA therapeutics. In pairing Revolution Biomanufacturing’s sequence engineering with BIOVECTRA’s integrated development and manufacturing solutions, we’re helping developers enhance protein expression, determine sequence faster, and move to the clinic with confidence.”
Normand Blais, Ph.D., AVP, Product Development of BIOVECTRA
The partnership is designed to reduce risks associated with supply chain complexity and process transfer while accelerating the development of mRNA-based therapeutics through a streamlined contract manufacturing model.
